For results for completed and on-going clinical trials in ovarian cancer for all drugs in a specific category, click on the drug category (e.g., Angiogenesis Inhibitors) on the left. To see only results for specific drugs in a class, click on the drug class for the drugs that interest you. For a schematic diagram of cell growth and survival pathways that these drugs inhibit, please scroll to the bottom of the page.

DNA DAMAGE REPAIR PATHWAY INHIBITORS PARP (Poly ADP-ribose Polymerase) Niraparib (Zejula™)
Olaparib (Lynparza™)
Pamiparib
Rucaparib (Rubraca™)
Talazoparib (Talzenna™)
Veliparib
ANTIBODY TARGETED DRUG CONJUGATES Antibody Drug Conjugates (ADC)

Targeting Mesothelin, MUC16, Axl, FRalpha,
Tissue Factor, NaPi2b

Anetumab Ravtansine
DMUC4064A
Enapotamab Vedotin
Mirvetuximab Soravtansine
Tisotumab Vedotin
XMT-1536
ANGIOGENESIS INHIBITORS VEGF, DLL4 Antagonists Bevacizumab (Avastin™)
Navicixizumab
VEGFR, PDGFR Inhibitors Cediranib
Lenvatinib
Pazopanib (Votrient™)
HORMONAL  THERAPY Aromatase Inhibitors

 

Anti-Estrogens

Anastrozole (Arimidex™)

Letrozole (Femara™)

Tamoxifen (Nolvadex™)

SIGNALING PATHWAY INHIBITORS PI3K/AKT/mTOR Pathway

Targeting PI3Kalpha, pan-PI3K, mTOR, TORC1/2

Alpelisib (Piqray™)
Everolimus (Afinitor™)
Temsirolimus (Torisel™)
Vistusertib
RAS/RAF/MAPK Pathway

Targeting MEK

Selumetinib
JAK/STAT Pathway

Targeting Stat3

Napabucasin
CELL CYCLE INHIBITORS CDK4/6 Inhibitors Palbociclib (Ibrance™)
CHK1/2 Inhibitors Prexasertib
p53 Activators APR-246
Wee1 Inhibitors Adavosertib
IMMUNOTHERAPY Checkpoint Inhibitors

Targeting CTLA-4, PD-1, PD-L1

Avelumab (Bavencio™)
Durvalumab (Imfinzi™)
Ipilimumab (Yervoy™)
Nivolumab (Opdivo™)
Pembrolizumab (Keytruda™)
Tislelizumab
Immune Cell Stimulators

Targeting IDO

Epacadostat
Vaccines

Targeting Tumor-associated Antigens, Survivin, TGFbeta, NY-ESO-1

DCVAC/OvCa
DPX-Survivac
Gemogenovatucel-T (FANG/Vigil™)
NY-ESO-1
Anti-Tumor Antibodies

Targeting FRalpha, CA125

Farletuzumab
Oregovomab

This diagram shows some of the key cell signaling pathways that are affected by genetic mutations or alterations found in ovarian cancers. The names of proteins encoded by the genes involved in various steps of each pathway are shown. Some proteins promote (indicated by an arrow) a particular step in the pathway and spur cell growth. Other proteins inhibit (indicated by the perpendicular symbol) a step in the pathway and prevent cells from growing and dividing in an uncontrolled way. Some genetic mutations/alterations result in a protein that is more active than it would normally be (shown in green), while others cause the protein to be less active (shown in red). A more active protein that stimulates cell growth or decreased activity of a protein that inhibits these processes can both lead to the uncontrolled growth seen in cancers.